Abstract Background Treatment of Plasmodium vivax malaria requires the clearing of
asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared …

Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …

Background. Tafenoquine is an 8-aminoquinoline developed as a more effective
replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine …

Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of
Plasmodium vivax, including dormant liver stages–so called hypnozoites. Its long half-life …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Plasmodium vivax causes debilitating but usually non-lethal malaria in most of Asia and
South America. Prevention of relapse after otherwise effective therapy for the acute attack …

Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but
the optimum duration of treatment and best partner drug are uncertain. A randomized …

Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …